ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,114.63
-0.01%
Dow Jones
44,546.08
-0.37%
US Dollar vs MXN
20.33975
0.17%
Brent Oil
74.855
0.84%
Bitcoin
96,086.18
-0.05%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Immutep Ltd (IMMP) Cotización

Immutep Ltd

Immutep Ltd (IMMP)

NASDAQ
1.96
0.01
(0.51%)
Cerrado 17 Febrero 3:00PM
Delayed by 15 minutes
1.95
-0.01
(-0.51%)
Fuera de horario: 6:43PM
Delayed by 15 minutes

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Estadísticas y detalles clave

Último Precio
1.95
Postura de Compra
1.86
Postura de Venta
2.13
Volume Operado de la Acción
96,467
1.9359 Rango del Día 2.01
0.00 Rango de 52 semanas 0.00
Capitalización de Mercado [m]
283.641M
Precio Anterior
1.95
Precio de Apertura
1.96
Hora
2000
@
1.95
(formt)
Última hora de negociación
Volumen financiero
US$ 190,441
Precio Promedio Ponderado
1.9742
Volumen promedio (3 m)
-
Acciones en circulación
145,456,785
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-1.12
Beneficio por acción (BPA)
-0.29
turnover
-
Beneficio neto
-42.72M

Acerca de Immutep Ltd

Immutep Ltd. is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesse... Immutep Ltd. is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's unique ability to stimulate or suppress the immune response. Immutep's lead clinical candidate, eftilagimod alpha ('efti'), is a soluble LAG-3 protein and first-in-class MHC Class II agonist that stimulates both innate and adaptive immunity to fight cancer. Mostrar más

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sitio web
www.immutep.com
Sede
Sydney, New South Wales, Aus
Fundado
-
Immutep Ltd is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IMMP. The last closing price for Immutep was US$1.95. Over the last year, Immutep shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Immutep currently has 145,456,785 shares in issue. The market capitalisation of Immutep is US$283.64 million. Immutep has a price to earnings ratio (PE ratio) of -1.12.

IMMP Últimas noticias

Más noticias

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
03 Febrero 2025
IMMP (0.51%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
12 Diciembre 2024
IMMP (0.51%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
10 Diciembre 2024
IMMP (0.51%)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

IMMP - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Immutep?
El precio actual de las acciones de Immutep es US$ 1.95
¿Cuántas acciones de Immutep están en circulación?
Immutep tiene 145,456,785 acciones en circulación
¿Cuál es la capitalización de mercado de Immutep?
La capitalización de mercado de Immutep es USD 283.64M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Immutep?
Immutep ha negociado en un rango de US$ 0.00 a US$ 0.00 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Immutep?
El ratio precio/beneficio de Immutep es -1.12
¿Cuál es la moneda de reporte de Immutep?
Immutep presenta sus resultados financieros en AUD
¿Cuál es el último beneficio anual de Immutep?
El último beneficio anual de Immutep es AUD -42.72M
¿Cuál es la dirección registrada de Immutep?
La dirección registrada de Immutep es LEVEL 12, 95 PITT STREET, SYDNEY, NEW SOUTH WALES, 2000
¿Cuál es la dirección del sitio web de Immutep?
La dirección del sitio web de Immutep es www.immutep.com
¿En qué sector industrial opera Immutep?
Immutep opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
JTAIJet AI Inc
US$ 6.02
(133.33%)
104.48M
SRMSRM Entertainment Inc
US$ 0.6999
(95.50%)
254.39M
WRDWeRide Inc
US$ 31.4877
(83.39%)
21.07M
INLFINLIF Limited
US$ 16.27
(80.58%)
7.68M
MBRXMoleculin Biotech Inc
US$ 2.1201
(66.94%)
136.66M
BLACBellevue Life Sciences Acquisition Corporation
US$ 3.08
(-56.31%)
430.77k
BLACUBellevue Life Sciences Acquisition Corporation
US$ 3.36
(-52.68%)
5.21k
CSAICloudastructure Inc
US$ 19.0001
(-49.58%)
1.03M
NEXNNexxen International Ltd
US$ 10.30
(-49.16%)
164.82k
BSLKBolt Projects Holdings Inc
US$ 0.6626
(-46.13%)
13.4M
CNSPCNS Pharmaceuticals Inc
US$ 0.1415
(31.26%)
489.28M
MGOLMGO Global Inc
US$ 0.7176
(-15.08%)
417.31M
SRMSRM Entertainment Inc
US$ 0.6999
(95.50%)
254.39M
INTCIntel Corporation
US$ 23.60
(-2.20%)
230.26M
NVDANVIDIA Corporation
US$ 138.85
(2.63%)
194.99M

IMMP Discussion

Ver más
Monksdream Monksdream 6 meses hace
IMMP 10 day hourly
👍️0
Monksdream Monksdream 7 meses hace
IMMP under $2
👍️0
Vector2112 Vector2112 7 meses hace
Refinitiv Logo
As of 06/27/2024

SellUnderperformHoldOutperformSelected Value:Buy
Refinitiv Stock Reports Plus
Refinitiv maintains a current price target of $8.64 for IMMP.
👍️0
glenn1919 glenn1919 7 meses hace
IMMP......................https://stockcharts.com/h-sc/ui?s=IMMP&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 7 meses hace
IMMP under $2
👍️0
Monksdream Monksdream 9 meses hace
IMMP under $3
👍️0
Monksdream Monksdream 1 año hace
IMMP under $2
👍️0
The Night Stalker The Night Stalker 2 años hace
nice
👍️0
The Night Stalker The Night Stalker 2 años hace
nice
👍️0
The Night Stalker The Night Stalker 2 años hace
nice
👍️0
The Night Stalker The Night Stalker 2 años hace
strong
👍️0
The Night Stalker The Night Stalker 2 años hace
nice
👍️0
The Night Stalker The Night Stalker 2 años hace
ready
👍️0
The Night Stalker The Night Stalker 2 años hace
nice
👍️0
The Night Stalker The Night Stalker 2 años hace
strong
👍️0
The Night Stalker The Night Stalker 2 años hace
watching
👍️0
The Night Stalker The Night Stalker 2 años hace
watching
👍️0
The Night Stalker The Night Stalker 2 años hace
dip
👍️0
The Night Stalker The Night Stalker 2 años hace
dip
👍️0
The Night Stalker The Night Stalker 2 años hace
nice
👍️0
The Night Stalker The Night Stalker 2 años hace
im in my bio DRMA, one at a time


RIGL rip for more
👍️0
The Night Stalker The Night Stalker 2 años hace
beast
👍️0
DewDiligence DewDiligence 2 años hace
IMMP +65% on interim (single-arm) phase-2 data for LAG-3 drug with Keytruda in NSCLC:

https://finance.yahoo.com/news/immutep-efti-combination-pembrolizumab-achieves-120000596.html

IMMP’s eftilagimod alpha is a LAG-3 protein that targets the same biologic pathway as BMY’s relatlimab, one of the component drugs (along with Opdivo) in Opdulag.

BMY’s Opdulag, which was FDA approved in Mar 2022 for first-line melanoma, is already selling at an annualized rate of $500M in the US alone (#msg-171784010).

Please see #msg-168259768 for related info.
👍️0
Invest-in-America Invest-in-America 2 años hace
IMMP: Very likely the hands-down WINNER of this Wall Street day, Peeps!!! (Just when ya thought that CANCER was no longer TRENDING.)

👍️0
stocks2watch stocks2watch 3 años hace
Going to move up
👍️0
make it happen make it happen 4 años hace
It's cool covered most average was $3.68
👍️0
calahan67 calahan67 4 años hace
I think you're not taking into account whats in the pipeline mainly several studies involving much larger pharmaceutical interested the immune boosting properties of eftaligamod. Imo this company and ceo are the real deal. Forget the outlays and remember its research and development that costs the most up front no matter what pharm you're talking about
👍️0
make it happen make it happen 4 años hace
More debt than revenue, large negatives on everything (cash flow, returns and profit margins.

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -300.79%

Management Effectiveness
Return on Assets (ttm) -20.00%
Return on Equity (ttm) -61.68%

Income Statement
Revenue (ttm) 6.35M
Revenue Per Share (ttm) 0.14
Quarterly Revenue Growth (yoy) -76.90%
Gross Profit (ttm) -6.66M
EBITDA -17.07M
Net Income Avi to Common (ttm) -27.36M
Diluted EPS (ttm) -0.4500

Total Debt (mrq) 9.75M
Book Value Per Share (mrq) 0.94

Cash Flow Statement
Operating Cash Flow (ttm) -14.67M
Levered Free Cash Flow (ttm) -7.67M
👍️0
sgunderbarth sgunderbarth 4 años hace
IMMP Interesting action....
👍️0
ClayTrader ClayTrader 4 años hace
* * $IMMP Video Chart 04-08-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
make it happen make it happen 4 años hace
Any positives in the numbers? Decent news but will need to raise money to keep anything going imho

IMMP is "ELIGIBLE" to receive development based milestones and sales based royalties. They do not have sales and drug is not out.


Profitability
Profit Margin 0.00%
Operating Margin (ttm) -300.79%

Management Effectiveness
Return on Assets (ttm) -20.00%
Return on Equity (ttm) -61.68%

Income Statement
Revenue (ttm) 4.85M
Revenue Per Share (ttm) 0.11
Quarterly Revenue Growth (yoy) -76.90%
Gross Profit (ttm) -6.66M
EBITDA -13.03M
Net Income Avi to Common (ttm) -20.89M
Diluted EPS (ttm) -0.4600

Balance Sheet
Total Cash Per Share (mrq) 0.65 will blow through it and need a serious capital raise imho
Total Debt (mrq) 7.45M
Book Value Per Share (mrq) 0.71

Cash Flow Statement
Operating Cash Flow (ttm) -11.2M
Levered Free Cash Flow (ttm) -5.86M
👍️0
make it happen make it happen 4 años hace
Had R/S a couple years ago and was $0.53 about a year ago
👍️0
make it happen make it happen 4 años hace
Quarterly growth -76.9%, returns are negative, zero profit and cash flow is very negative.

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -300.79%

Management Effectiveness
Return on Assets (ttm) -20.00%
Return on Equity (ttm) -61.68%

Income Statement
Revenue (ttm) 4.85M
Revenue Per Share (ttm) 0.11
Quarterly Revenue Growth (yoy) -76.90%
Gross Profit (ttm) -6.66M
EBITDA -13.03M
Net Income Avi to Common (ttm) -20.89M
Diluted EPS (ttm) -0.4600

Balance Sheet
Total Cash Per Share (mrq) 0.65
Total Debt (mrq) 7.45M
Book Value Per Share (mrq) 0.71

Cash Flow Statement
Operating Cash Flow (ttm) -11.2M
Levered Free Cash Flow (ttm) -5.86M
👍️0
make it happen make it happen 4 años hace
I agree it states that Novartis is in chagre and IMMP is "ELIGIBLE" to receive milestones and payments. Previous reverse split. IMHO prob going to be bled
👍️0
reverse_long reverse_long 4 años hace
IMMP never holds any spikes. Every time it has fastrack or patent news it dumps away. It is the real deal to dump very hard. GLTA!
👍️0
calahan67 calahan67 4 años hace
This is the real deal folks
👍️0
ClayTrader ClayTrader 4 años hace
* * $IMMP Video Chart 03-25-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
DewDiligence DewDiligence 4 años hace
IMMP up on BMY's LAG-3 coattails: #msg-162784750.
👍️0
calahan67 calahan67 4 años hace
And they have a very sharp ceo if you've seen any of their videos he tells it straight up imo
👍️0
calahan67 calahan67 4 años hace
Up huge on no news a great big sleeper imo
👍️0
calahan67 calahan67 4 años hace
Looks like accumulation is beginning a slow churn higher
👍️0
everything everything 4 años hace
Interesting company, looks to be in reversal but dip opportunity may be in the works.
👍️0
akamaii akamaii 4 años hace
Like it here
👍️0
lecorb lecorb 4 años hace
$IMMP: TIPRANKS, SCORE, UPGRADE TO 10 OUTPERFORM! ANALIST RATINGS: PT: $6.50 MODERATE BUY! LOW: @5.50, MED:@6.50, HI: $8.00 Jason McCarthy Maxim Group 5 Stars target $8.00 ranking Buy analystAction Reiterated date 6 days ago Last calification.
👍️0

Su Consulta Reciente

NASDAQ
IMMP
Immutep
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios